CriticalSelective serotonin reuptake inhibitors×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1), and fluoxetine is a selective serotonin reuptake inhibitor (SSRI). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with SSRIs, including fluoxetine (St John's wort SmPC, AEMPS, section 4.5). The fluoxetine SmPC lists St John's wort among serotonergic agents with which mild cases of serotonin syndrome have been reported in patients taking SSRIs (fluoxetine SmPC, AEMPS, section 4.5). Fluoxetine and its active metabolite norfluoxetine are eliminated slowly: the half-life is 4–6 days for fluoxetine and 4–16 days for norfluoxetine, and the drug remains in the body for 5–6 weeks after it is stopped (fluoxetine SmPC, AEMPS, section 5.2). The SmPC says to take this long elimination into account when assessing interactions, for example when switching from fluoxetine to another antidepressant (fluoxetine SmPC, AEMPS, section 4.5).
Symptoms
According to the Spanish fluoxetine summary of product characteristics (SmPC), serotonin syndrome can be life-threatening. Its features are hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, confusion, irritability and extreme agitation that may progress to delirium and coma (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). The fluoxetine label of the US Food and Drug Administration (FDA) also lists hallucinations, dizziness, sweating, flushing, tremor, hyperreflexia, incoordination, seizures, nausea, vomiting and diarrhoea (FDA fluoxetine label, section 5.2). The Spanish fluoxetine SmPC also mentions mild cases of the syndrome with serotonergic agents, St John's wort among them (fluoxetine SmPC, AEMPS, section 4.5). The European Medicines Agency (EMA) herbal monograph says it occurs very rarely with serotonin reuptake inhibitors (St John's wort herbal monograph, EMA, section 4.5).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and its interaction table names fluoxetine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The fluoxetine SmPC is less strict: use the combination with caution and with more frequent and closer clinical follow-up (fluoxetine SmPC, AEMPS, section 4.5). If serotonin syndrome occurs, stop fluoxetine and start supportive symptomatic treatment (fluoxetine SmPC, AEMPS, section 4.4); the label of the US Food and Drug Administration (FDA) also says to stop other serotonergic medicines immediately (FDA fluoxetine label, section 5.2). When switching from fluoxetine to another antidepressant, take its long half-life into account (fluoxetine SmPC, AEMPS, section 4.5): it remains in the body for 5–6 weeks after it is stopped (same SmPC, section 5.2). No document says how long to wait between stopping St John's wort and starting fluoxetine. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, European Medicines Agency, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prozac (fluoxetine) prescribing information (2026)– FDA label, DailyMed setid c88f33ed-6dfb-4c5e-bc01-d8e36dd97299, version 59, revised 01/2026, section 7.7 Drugs Metabolized by CYP2D6
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5